Extracellular mRNAs (ex-mRNAs) potentially supersede extracellular miRNAs (ex-miRNAs) and other 28 RNA classes as biomarkers. Here, we present a comprehensive extracellular RNA (exRNA) study in 29 human blood circulation based on conventional small RNA-sequencing (sRNA-seq) and sRNA-seq after 30 T4 polynucleotide kinase (PNK) end-treatment of total exRNA isolated from serum and platelet-poor 31 EDTA, ACD, and heparin plasma. Applying strict criteria for read mapping and annotation, we found that 32 compared to conventional sRNA-seq PNK-treatment increased the detection of informative ex-mRNAs 33 reads up to 50-fold. Based on captured ex-mRNAs from healthy individuals, we concluded that the 34 exRNA pool is dominated by hematopoietic cells and platelets, with additional contribution from the 35 liver.
Introduction 48
Extracellular RNAs (exRNAs) in biofluids were described as early as the first half of the 20th century 1 49 but underwent a more recent renaissance with the detection of circulating miRNAs 2 . Despite the high 50 nuclease activity in biofluids, miRNAs (ex-miRNAs) remain detectable due to protection by tightly 51 bound RNA-binding proteins and/or inclusion in microvesicles 2-5 . In recent years, especially with the 52 advancement of RNA-sequencing (RNA-seq), an extensive body of research accumulated regarding the 53 role of extracellular miRNAs in a broad range of medical conditions and cardiovascular diseases, 54 including advanced heart failure 6 and myocardial infarction 7 . 55 56 Ex-miRNAs are remarkably stable in circulation, and we recently showed that distinct ex-miRNA 57 signatures can be followed for months 8 . However, a general limitation of ex-miRNAs is the relatively low 58 number of miRNA genes with only few tissue specific members 9 . Alterations of ex-miRNAs are often 59 difficult to interpret biologically as they either affect ubiquitously expressed or low-abundance miRNAs 60 without a clearly identifiable source tissue. In contrast, the number of mRNA genes in the human genome 61 is at least an order of magnitude higher 10 providing a much better tissue and functional resolution for 62 physiological conditions or disease states. While RNA-sequencing (RNA-seq) potentially offers the most 63 comprehensive interrogation of ex-mRNAs and their changes lack of robust protocols and challenges in 64 the analysis of fragmented, short reads hampered their study. 65 66 Technical challenges in exRNA profiling encompass the very low amounts of RNA in body fluids, and 67 the influence of anticoagulants used for blood collection, increasing the likelihood for batch effects or 68 spurious findings 11, 12 . The type of blood sample used for RNA isolation can substantially influence the 69 stability of certain ribonucleoprotein (RNPs) complexes and associated RNAs. A striking example for 70 differential stability of RNPs with different anticoagulants is the loss of 5' tRNA fragments using 71 magnesium-ion-chelating EDTA or citrate salts for blood collection 6,13 . While it seems likely that these 72 routinely used chelators for blood collections will impact the stability of other extracellular RNPs, the 73 overall extent in which the sample types influence the exRNA profile remains unknown. 74 75 By design sRNA-seq cDNA protocols enrich for miRNAs, which carry 5' phosphate and 3' hydroxyl 76 groups. However, in body fluids other classes of RNAs, including potentially mRNAs, most likely exist 77 as degradation products due to the high nuclease activity 8 . RNA degradation products possess 5' OH ends 78 as well as 2' or 3' phosphate or 2',3' cyclic phosphate termini. These termini are incompatible with 79 sRNA-seq, and fragments of those RNAs will largely escape detection. Enzymatic treatment of RNA ends 80 by T4 polynucleotide kinase (PNK) rescues RNA fragments devoid of the necessary termini and has been 81 used for different RNA-seq based applications including exRNA studies 14, 15 . However, an effect on ex-82 mRNA capture has not been shown thus far. 83 84 Here, we used a recently published RNA isolation protocol that quantitatively recovers exRNAs 8 , and 85 combine T4 PNK RNA end-modification with sRNA-seq and stringent read annotation criteria to 86 demonstrate effective and informative capture of ex-mRNAs. We investigated blood samples with 87 different commonly used anticoagulants to identify confounding factors, and finally tested the potential of 88 ex-mRNAs in a proof-of-concept cohort of patients presenting with an acute coronary syndrome. 89
Methods 90

Sample procurement 91
Blood was collected from healthy volunteers and from patients evaluated for acute coronary syndrome at 92
The Rockefeller University and Mannheim University Medical Centre, respectively, by the first author. 93
Human tissue samples for bulk mRNA-seq were obtained from the National Disease Research 94 Interchange (Philadelphia), or from biopsies or discarded surgical waste. Sample procurement was 95 approved by the institutional review boards of all participating institutions. All participants gave written 96 informed consent, and the studies were approved by the IRBs of the participating institutions. 97
RNA isolation 98
ExRNA was isolated from 425 µl cell-free serum or platelet-depleted plasma using a customized RNA 99 isolation protocol developed to minimize residual nuclease activity 8 ; the RNA was purified using silica 100 columns. Cellular or tissue total RNA was extracted using TRIzol with an additional phenol/chloroform 101 extraction step and concentrated by alcohol precipitation. 102
PNK treatment of total exRNA 103
After elution from the silica column, half of the isolated total exRNA was used directly for sRNA-seq, 104 and the other half treated with T4 PNK in a total reaction volume of 20 µl for 30 min at 37 °C followed 105 by re-purification and elution of the PNK treated RNA using the same silica column, and then subjected 106 to sRNA-seq library preparation. 107
Small RNA-seq 108 sRNA-seq cDNA library preparation was done as described 16 but size selecting from 19-to 45-nt. Long 109 mRNAseq of cells and tissues was done using the Illumina Stranded mRNA-seq TruSeq protocol 110 Plasma and serum were collected from six healthy volunteers. Collection tubes for plasma samples 137 contained the divalent-metal-ion-chelating EDTA and ACD salts or the polyanion heparin. All plasma 138 samples were platelet-depleted, and total exRNA was recovered by our recently published isolation 139 protocol which preserves RNA integrity and quantitatively recovers exRNA 8 . Multiplexed sRNA-seq 140 libraries were generated minimizing batch effects (libraries 1-4; Fig. 1, Supplementary Data 1) . 141
142
More than 95% of the processed reads were 12-to 42-nt in length. Such short reads impose challenges for 143 confident transcript assignment due to multi-mapping. For conventional sRNA-seq, i.e. miRNA studies, 144 this is minimized by hierarchical mapping and requiring a minimum read length of 16-nt 17 . Hierarchical 145 mapping ensures that more abundant RNAs like rRNAs and tRNAs take precedence over less abundant 146 classes like mRNAs and miRNAs if a sequence matches to more than one RNA class. To arrive at a 147 comprehensive assessment, we initially retained reads <16-nt. With that, over 80% of reads mapped to 148 established classes of human RNAs and human genome with the expected enrichment for miRNAs in the 149 untreated samples (Fig. 1B) . The most apparent difference after PNK-treatment was the increase in the 150 rRNA fraction. A residual 3-15% of reads mapped to the E. coli genome, and ~1% to bacterial expression 151 plasmids and diatoms (Supplementary Data 1). Bacterial RNA is a common contaminant in 152 recombinantly produced enzymes used for library preparation and residual diatom RNA exists in 153 commercial silica matrices used for nucleic acid isolation. In standard RNA-seq applications using higher 154 amounts of input RNA, these sequences do not influence the results but they can contribute a sizeable 155 fraction of sequence reads in low input samples like body fluids 6, 8 . 156
157
Ex-mRNA reads comprised 6.5 to 20% with some enrichment after PNK-treatment in EDTA and ACD 158 plasma but not in heparin plasma or serum ( Fig. 1B ). Further review of read alignments, however, showed 159 that untreated samples collected more mRNA reads with 1 or 2 mismatches, i.e. inflating the mRNA read 160 count by inclusion of low-confidence reads (Supplementary Data 2). As expected, reads <15-nt had a high 161 fraction of multi-mapping ( Supplementary Fig. 1 ). Therefore, our final ex-mRNA analysis was restricted 162 to perfectly mapping reads (0 mismatch) 15-nt or longer with at most two mapping locations. The latter 163 was necessary to account for the identical coding sequences of the hemoglobin paralogs HBA1 and 164 HBA2 that would otherwise be underrepresented. 
Ex-mRNAs in circulation originate mostly from the coding sequences and not UTRs 175
It has been previously reported, that ex-mRNAs in cell culture media mostly originate from the 3' UTR of 176 mRNA transcripts 20 . Review of read alignments in our study, however, indicated that most of the 177 ex-mRNA reads originated from the transcript coding sequence (CDS), a pattern that was only observable 178 in PNK-treated samples due to better transcript coverage. Read distribution and read length were 179 reminiscent of ribosome-profiling data, which indicated that ex-mRNA fragments are ribosome protected 180 and circulate as polysome or monosome complexes. This observation was confirmed by a metagene 181 analysis that was based on an average of 12,789 to 16,486 ex-mRNA transcripts depending on sample 182 type. This showed that ~60% of the reads originated from the CDS and ~30% from the 3' UTR ( Fig. 2) . 183
Anticoagulants have a widespread effect on the exRNA profile 184
The anticoagulants we studied are the predominant ones used to collect blood samples in clinical practice 185 and for research purposes. All of them influence blood cells ex vivo 21-23 , and heparin 186 may not be removed sufficiently by common extraction protocols and as a result interfere with 187 downstream applications 24 . This is especially relevant if patient populations are studied that often receive 188 high doses of heparin. 189
190
We therefore next looked at how sample type influenced the measured exRNA composition for both the 191 untreated and PNK-treated samples. We noted the previously reported destabilization of 5' tRNA 192 fragments in EDTA and ACD samples ( Supplementary Fig. 2 ) 6,13 , and alterations in miRNA composition 193 between serum and platelet-depleted EDTA plasma 12 . In an ANOVA-like comparison we observed 194 abundance differences for 86 miRNAs in the untreated samples and of 1,458 mRNA transcripts in the 195
PNK-treated samples between the three plasma types and serum (Supplementary Data 3 and 4). Serum 196
generally had a higher abundance of ex-miRNAs (e.g. miR-223 and -142) and ex-mRNAs (e.g. S100A8) 197 enriched in myeloid cells and platelets. In a gene set analysis ex-mRNAs abundant in serum were 198 associated with inflammation and leukocyte activation whereas plasma ex-mRNAs were more related to 199 general cellular processes like translation (Supplementary Data 5). Although there was a high degree of 200 similarity between the exRNA profiles of EDTA and ACD plasma, as expected from their mechanism of 201 action ( Supplementary Fig. 3B ), there were distinctive differences as well. For instance, EDTA plasma 202 had increased levels of erythropoietic transcripts, i.e. miR-451(1) and hemoglobin mRNAs, compared to 203 all other samples. ACD had 3-to 4-fold higher levels of miR-150(1), a lymphocyte-restricted miRNA, 204 than the other sample types ( Supplementary Fig. 3A , Supplementary Data 3 and 4). 205
206
The destabilizing effect of the chelating reagents, ACD and EDTA, on ribonucleoprotein complexes was 207 not restricted to tRNAs. Both altered read coverage signatures of other RNAs. Human small nuclear 208
RNAs U1 and U2 snRNAs are ~164-nt and ~190-nt non-coding RNAs, respectively, which assemble with 209 proteins into small nuclear ribonucleoproteins (snRNPs). Biochemical studies demonstrated that U1 and 210 U2 possess core structures that are relatively resistant to nuclease digestion 25 . In high magnesium 211
conditions several U1 domains are protected from nuclease digestion whereas in low magnesium 212 conditions, i.e. after the addition of EDTA or similar chelating reagents, only the core region remained 213 relatively resistant to digestion. Our sRNA-seq data agreed well with these earlier observations 214 ( Supplementary Fig. 3C ). In addition, the coverage of the more protected core region was 4-to 8-fold 215 lower in EDTA and ACD plasma, respectively, than in the other two sample types. There was no 216 difference in read coverage patterns for snRNAs U2, U4, U5, and U6 or the large ribosomal subunits, 18S 217 and 28S, between the different sample types. 218
Hematopoietic cells, platelets, and liver are the major sources of exRNAs in healthy individuals 219
We next sought to identify contributing tissue sources to the exRNA pool in the physiological state. We 220 generated a polyA mRNA-seq tissue atlas comprising major human cell and tissue types and calculated a 221 tissue specificity score (TSS) 10 for all of the 19,810 mRNAs as defined in Ensembl release 82 222 (Supplementary Data 6). Genes restricted to a few tissues or cell types had a TSS greater than 3, e.g. 223 aldolase B (ALDOB) expressed in liver and kidney, while classic marker genes like albumin (ALB) or 224 cardiac troponin T (TNNT2) had a TSS greater than 4. 225 226 A total of 3,167 ex-mRNAs entered comparative analysis, and of those 144 had a TSS > 3 (102 >3 but <4, 227 42 >4; Supplementary Data 7), therefore being most informative regarding tissue of origin. About 30% of 228 the 144 mRNAs were most abundant in neutrophils, 10% in liver, and 5% each in red blood cells (RBCs), 229 platelets, and skeletal muscle. Conversely, when we compared the 1,000 highest expressed mRNAs for 230 each tissue in the atlas to the 3,167 ex-mRNAs, we found a much higher fraction of the top 1,000 231 transcripts from RBCs, platelets, neutrophils, PBMC, and monocytes captured in circulation than from 232 any of the other tissue ( Fig. 3 and 4 , Supplementary Fig. 4 , Supplementary Data 8). Our annotation 233 criteria led to the detection of certain highly tissue-specific genes from other tissues, e.g. MYBPC3 234
(myocardium), SFTPB (lung), or MIOX (kidney; Supplementary Fig. 4 ) in some serum or plasma sample 235 types. However, the underlying reads were repetitive and short and therefore highly suggestive of 236 annotation artefacts. 237
238
We noted, again, a clear difference between sample types. In EDTA and ACD plasma we detected 12% to 239 21% of the top 1,000 hematopoietic mRNAs. This percentage increased to 27% to 49% in heparin, and 240 38% to 81% in serum. Particularly striking was this difference for neutrophils, for which we detected 241 17%, 49%, and 81% of the 1,000 most highly expressed transcripts in ACD, EDTA, and serum, 242 respectively, as ex-mRNAs ( Fig. 4 , Supplementary Fig. 4 Supplementary Data 8) . The increase of 243 ex-mRNAs in serum compared to the other samples is likely related to in vitro neutrophil degranulation 244 and apoptosis during coagulation. On the mRNA level this is much more pronounced for neutrophil than 245 platelets transcripts, of which we detected 35% in heparin and 42% in serum. Although miRNAs have 246 been reported as markers for platelet activation 12 , our data suggest that neutrophils also contribute to 247 coagulation-dependent miRNA abundance changes. 248
249
In summary, these results indicated that hematopoietic cells, platelets, and the liver are main contributors 250 to the ex-mRNA profile and based on our data there was little support that other solid tissues contribute 251 substantially. 252
RNA end-modification increases the diagnostic potential of exRNA in disease 253
To evaluate the clinical potential of ex-mRNAs in patients we studied exRNA changes in a pilot cohort of 254 patients with an acute coronary syndrome (ACS; n = 6) and age-and gender-matched healthy controls (n 255 = 10; Supplementary Data 1 and 9). All patients had evidence of myocardial necrosis based on elevated 256 cardiac troponin I levels, highly-sensitive and routinely used marker for myocardial damage. Patients with 257 myocardial injury provided a good proof-of-concept cohort as the myocardium is one of the few tissues 258 expressing tissue-specific miRNAs (myomirs miR-208a, -208b, and -499), which have been shown to be 259 elevated in the circulation of these patients. In comparison to the controls the ACS group had higher white 260 blood cell counts (Supplementary Data 9 and 10). 261 262 Because the ACS group received high doses of heparin before sample collection as part of , all patient and 263 control samples were collected in heparin plasma to avoid any biases associated with different 264 anticoagulants as described before. Two small RNA-seq libraries were generated from untreated (library 265 5) and PNK-treated (library 6) total RNA ( Supplementary Fig. 5 ). Unsupervised hierarchical clustering of 266 the 3'-adapter spike-in small RNAs did not separate the two groups, arguing against any potential bias 267 due to residual heparin in the samples ( Supplementary Fig. 6 ). 268 269
In the differential analysis 18 miRNAs were altered in the untreated samples, 11 higher and 7 lower in 270 ACS than controls ( Fig. 5A; Supplementary Data 11) . The myocardium-specific miRNA miR-208b(1) in 271 the ACS group was 17-fold higher than in the controls, the other two myocardium-specific miRNAs miR-272 208a (FDR 0.07%) and miR-499 (FDR 0.15%) were elevated 8-fold in ACS. These changes were in line 273 with release due to myocardial injury and in magnitude similar to what we reported for patients in 274 advanced heart failure 6 , and again supporting that any heparin-associated bias did not substantially 275 influence this comparison. Individual myeloid-enriched miRNAs were elevated in ACS as well, e.g. miR-276 223(1), while platelet miRNAs in general were not changed (Fig. 5A) . Data 6) and many specifically expressed in this cell type. The reads of the released neutrophil transcripts 288 originated again mainly from the CDS of the transcripts (Fig. 5E) . In contrast to our observations with 289 myocardium-specific miRNAs, we did not detect any myocardial mRNAs in circulation. 290
291
Taken together, these data support that ex-mRNAs a neutrophil signature in the ACS group with a release 292 of ribosome-associated transcripts, a change not detectable on the miRNA level. 293
Discussion 294
Here, we showed that mRNA fragments in circulation (ex-mRNAs) can be efficiently captured by T4 295 polynucleotide kinase (PNK) end-treatment of total extracellular RNA (exRNA) followed by sRNA-seq. 296
Ex-mRNAs provide superior tissue and functional resolution for most conditions compared to other RNA 297 classes because of the higher number of comparatively well annotated, highly expressed tissue-restricted 298 transcripts. Tissue-specific ex-miRNAs, in selected cases, offer complementary information. 299 300 Ex-miRNAs have been widely studied as biomarkers in many types of diseases and conditions 6,7,26,27 . 301
They perform well in the detection of tissue damage of organs with tissue-specific miRNAs like the liver 302 (miR-122) 28 or the heart (myomirs) 6,7 . Individual miRNAs alone or in combination are also used for risk 303 prediction for chronic conditions 27 , and characteristic ex-miRNA changes have been shown to be stable 304 over months even in the absence of detectable illness 8 . But the precise tissue-source or etiology of such 305 differences based on the ex-miRNA profile remain unclear. Many tissues do not possess specifically-306 expressed miRNAs, and measurements of ubiquitously or weakly expressed miRNAs in biofluids are 307 prone to misinterpretation. 308
309
Patients with acute coronary syndrome (ACS) represented a good benchmark population to evaluate our 310 analysis of ex-mRNAs given the consistently reported elevations of myocardium-specific miRNAs 311 (myomirs) in circulation 6,7 . As expected, myomirs were elevated in ACS but aside from these changes 312 few alterations were detectable between ACS and healthy controls on the ex-miRNA level. However, the 313 ACS group had a characteristic neutrophil ex-mRNA signature in circulation, i.e. elevated levels of 314 neutrophil-enriched and -specific genes. Although this finding needs validation in larger cohorts and 315 could have been confounded by the higher leukocyte count in the ACS group, the results are in line with 316 the increasing recognition of inflammation and neutrophil activation for atherosclerotic disease. 317
Endothelial damage and neutrophil activation have been linked to thrombus formation in animal studies 29 , 318 and neutrophils in atherosclerotic plaques are detectable in animal models as well as human samples 30 . 319
Irrespective of the reason for the neutrophil signature in the ACS cohort, i.e. an inflammatory response to 320 ACS or due to higher neutrophil counts, the results clearly emphasize the superior tissue resolution of ex-321 mRNAs compared to ex-miRNAs. The lack of detectable myocardial ex-mRNAs in any of the samples 322 used in this study is most likely due to the low sequencing depth of ex-mRNAs caused mainly by large of 323 rRNA fractions but differential stability of ex-miRNAs and ex-mRNA fragments likely contributes 5 . 324 325 While our study did not address different mechanisms of exRNA release or the different compartments of 326 exRNAs currently discussed, a few findings suggest that ex-mRNAs and probably a large part of all 327 exRNA circulate within polysome complexes. First, in ex-mRNAs transcripts sequenced with good 328 coverage, i.e. high abundance transcripts, read length (~28-nt) and read distribution across the transcripts 329 were reminiscent of sequencing data from ribosome profiling studies 31 . Second, the loss of 5' tRNA 330 halves in EDTA and ACD samples 6,13 is consistent with loss of protection by the RNA-binding protein 331 ZNF598 after polysome disassembly due to Mg2+ chelation. We have recently shown that ZNF598 binds 332 tRNAs and translating ribosomes 32 , and the circulating tRNA halves correspond precisely to the region 333 protected by the ZNF598. Chelation of Mg2+ by EDTA, traditionally used experimentally for that 334 purpose 25,33 , and ACD in blood collection tubes will lead to disassembly of polysomes render the 335 associated tRNAs vulnerable to nuclease digestion. The more widespread effect of RNP destabilization 336 after Mg2+ chelation is furthermore evident by loss of RNA fragments from certain regions of U1 RNA, 337 and overall fewer captured transcripts in EDTA and ACD samples though it ultimately remains unclear 338 how much ex vivo effects of the different plasma additives on hematopoietic cells contribute to these 339 differences [21] [22] [23] . Aside from the utility to study in vivo changes of exRNAs and to develop diagnostic 340 applications, the discriminatory value of ex-mRNA compared to other RNA classes can also be utilized to 341 assess such changes and biases related to blood collection and processing, which are well known in 342 laboratory medicine and of which the effects of EDTA and ACD are the most prominent. 343
344
The finding that most reads originate from the coding sequence and not the UTRs is in contrast to a recent 345 report by Skog et al. 15 and likely due to different sRNA-seq protocols and analysis strategies. In fact, 346 while Skog et al. and Danielson et al. 14 used RNA end-treatment with RNA-seq they did not report 347 enrichment of ex-mRNAs. In our study, strict mapping criteria were necessary to increase the signal-to-348 noise ratio for ex-mRNAs. 349
The adoption of exRNAs as clinical biomarkers will require quantitative and reasonably fast assays like 350 qPCR. However, primer design for short fragments is challenging, and qPCR like other not-sequencing 351 based assays does not easily allow to verify the amplified signal (i.e. read sequence). The diminutive 352 amounts of RNA in body fluids increases the risk of introducing biases. For instance, up to 30% of reads 353 in samples not end-treated with T4 PNK in this study mapped to the plasmid of Rnl2 ligase, which is used 354 for adapter ligation during the sRNA-seq cDNA preparation. Omitting this plasmid reference from the 355 mapping hierarchy during sequence read alignments resulted in a substantial amount of plasmid 356 sequences aligning perfectly to other RNA classes, including mRNA transcripts, even using the most 357 stringent mapping criteria. Similar considerations will have to be taken into account with different 358 methods or further refinements, like e.g. using heparinase treatment to reduce possible interference of 359 heparin with enzymatic reactions, or enzymatic rRNA removal. 360
361
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